Advanced BioMedical Technologies, Inc.: 10-Q filed 2020-09-21

Name: Advanced BioMedical Technologies, Inc.: 10-Q filed 2020-09-21
Creator: Advanced BioMedical Technologies, Inc.
License: https://creativecommons.org/licenses/by/4.0/

What Advanced BioMedical Technologies, Inc. reported in its quarterly report filed 2020-09-21 (fiscal Q3 2020): 36 published measures, 106 facts as tagged in accession 0001493152-20-018065.

This filing

Form: 10-Q (quarterly report)
Filed: 2020-09-21
Fiscal period: fiscal Q3 2020
Accession: 0001493152-20-018065 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Advanced BioMedical Technologies, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2020-07-31	281,639	USD
At 2019-10-31	218,500	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2020-07-31	-6,993,007	USD
At 2020-04-30	-6,720,049	USD
At 2020-01-31	-6,641,855	USD
At 2019-11-02	-6,481,165	USD
At 2019-10-31	-6,478,239	USD
At 2019-07-31	-6,370,174	USD
At 2019-04-30	-6,280,518	USD
At 2019-01-31	-6,080,031	USD
At 2018-10-31	-5,619,012	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2020-07-31	14,474	USD
At 2019-10-31	5,592	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	-205,225	USD	92
2019-11-01 to 2020-07-31	-478,666	USD	274
2020-02-01 to 2020-04-30	-209,652	USD	90
2019-11-03 to 2020-01-31	-63,789	USD	90
2019-11-01 to 2020-01-31	-63,789	USD	92
2019-05-01 to 2019-07-31	-212,876	USD	92
2018-11-01 to 2019-07-31	-701,078	USD	273
2019-02-01 to 2019-04-30	-252,523	USD	89
2018-11-01 to 2019-01-31	-252,523	USD	92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2019-11-01 to 2020-07-31	-105,512	USD	274
2018-11-01 to 2019-07-31	-550,039	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2019-11-01 to 2020-07-31	29,692	USD	274
2018-11-01 to 2019-07-31	12,437	USD	273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	961	USD	92
2019-11-01 to 2020-07-31	61,251	USD	274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2019-11-01 to 2020-07-31	143,975	USD	274
2018-11-01 to 2019-07-31	588,120	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2019-11-01 to 2020-07-31	-29,692	USD	274
2018-11-01 to 2019-07-31	-34,027	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2020-07-31	-10,063,030	USD
At 2019-10-31	-9,581,438	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	69,974,850	shares	92
2019-11-01 to 2020-07-31	69,929,959	shares	274
2019-05-01 to 2019-07-31	69,624,850	shares	92
2018-11-01 to 2019-07-31	69,624,850	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	70,214,850	shares	92
2019-11-01 to 2020-07-31	70,062,222	shares	274
2019-05-01 to 2019-07-31	69,624,850	shares	92
2018-11-01 to 2019-07-31	69,624,850	shares	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2020-07-31	109,778	USD
At 2019-10-31	99,034	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	4,400	USD	92
2019-11-01 to 2020-07-31	10,867	USD	274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	-116,441	USD	92
2019-11-01 to 2020-07-31	-336,420	USD	274
2019-05-01 to 2019-07-31	-125,429	USD	92
2018-11-01 to 2019-07-31	-443,866	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2020-07-31	129,553	USD
At 2019-10-31	119,466	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2020-07-31	7,264,617	USD
At 2019-10-31	6,696,739	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	116,582	USD	92
2019-11-01 to 2020-07-31	363,840	USD	274
2019-05-01 to 2019-07-31	125,429	USD	92
2018-11-01 to 2019-07-31	443,866	USD	273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2020-07-31	80,362	USD
At 2019-10-31	64,107	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	141	USD	92
2019-11-01 to 2020-07-31	27,420	USD	274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	42,773	USD	92
2019-11-01 to 2020-07-31	140,858	USD	274
2019-05-01 to 2019-07-31	48,081	USD	92
2018-11-01 to 2019-07-31	81,103	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2020-07-31	69,974,850	shares
At 2019-10-31	69,874,850	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2020-07-31	280,115	USD
At 2019-10-31	334,363	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2020-07-31	42,308	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2020-07-31	44,960	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2020-07-31	569,322	USD
At 2019-10-31	534,666	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2020-07-31	459,544	USD
At 2019-10-31	435,632	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2020-07-31	34,717	USD
At 2019-10-31	49,767	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	-205,225	USD	92
2019-11-01 to 2020-07-31	-478,666	USD	274
2019-05-01 to 2019-07-31	-212,876	USD	92
2018-11-01 to 2019-07-31	-701,078	USD	273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	-205,225	USD	92
2019-11-01 to 2020-07-31	-478,666	USD	274
2019-05-01 to 2019-07-31	-212,876	USD	92
2018-11-01 to 2019-07-31	-701,078	USD	273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	-280,767	USD	92
2019-11-01 to 2020-07-31	-532,914	USD	274
2019-05-01 to 2019-07-31	-92,845	USD	92
2018-11-01 to 2019-07-31	-760,706	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	54,772	USD	92
2019-11-01 to 2020-07-31	166,833	USD	274
2019-05-01 to 2019-07-31	71,127	USD	92
2018-11-01 to 2019-07-31	346,529	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	3,938	USD	92
2019-11-01 to 2020-07-31	13,014	USD	274
2019-05-01 to 2019-07-31	6,221	USD	92
2018-11-01 to 2019-07-31	16,234	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2020-05-01 to 2020-07-31	-88,784	USD	92
2019-11-01 to 2020-07-31	-142,246	USD	274
2019-05-01 to 2019-07-31	-87,447	USD	92
2018-11-01 to 2019-07-31	-257,212	USD	273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2019-11-01 to 2020-07-31	18	USD	274
2018-11-01 to 2019-07-31	21	USD	273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2019-11-01 to 2020-07-31	15,557	USD	274
2018-11-01 to 2019-07-31	36,058	USD	273

Inspect the source

Entity: Advanced BioMedical Technologies, Inc. / CIK 0001385799
Captured: 2026-09-22 19:45 UTC
SEC response SHA-256: 1591f8b0cfab5a80255c1912235608d48fec8b1551b4e091e75b1bc63071e992

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385799.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))